Influvac (Influenza Virus B/Austria/1359417/2021-Like Strain (B/Austria/1359417/2021, Bvr-26), Influenza A/Vic)

The vaccine contains inactivated virus antigens from selected influenza A and B strains. After injection, antigen‑presenting cells process these proteins and activate T‑cells, which in turn stimulate B‑cells to produce strain‑specific neutralising antibodies. These antibodies provide immunity that can prevent or lessen disease if the person is later exposed to the matching viruses.

The prescribed dose of Influvac is determined by a qualified healthcare professional. Typically, a single intramuscular or subcutaneous injection is given each influenza season, but the exact volume and administration schedule are set by the prescriber based on age, health status, and local immunisation guidelines.

Safety data for Influvac in pregnancy are limited, and the vaccine should only be used when the potential benefits outweigh any theoretical risks. Women who are breastfeeding may receive the vaccine, but they should discuss any concerns with their obstetrician or primary care provider before vaccination.

To order Influvac, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After the request, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details (including cold‑chain handling) and any required import documentation.

Influvac is a split‑virus, inactivated vaccine that includes the latest circulating A and B strains, similar to many other seasonal flu vaccines. Compared with live‑attenuated nasal sprays, Influvac is administered by injection and is suitable for a broader age range, including individuals with certain medical conditions where live vaccines are contraindicated.

Influvac must be stored refrigerated at 2 °C to 8 °C. It should be kept in its original packaging, protected from light, and must not be frozen or shaken. During transport, a validated cold‑chain system is required to maintain the temperature range and preserve vaccine potency.

Influvac is administered by a single intramuscular or subcutaneous injection, usually into the deltoid muscle of the upper arm. The injection is performed by a qualified healthcare professional using aseptic technique. The site should be observed for a short period after vaccination for any immediate reactions.

The most serious adverse events associated with Influvac are severe allergic reactions (anaphylaxis) and the rare occurrence of Guillain‑Barré syndrome. Recipients should be monitored for at least 15 minutes after injection, and any signs of difficulty breathing, swelling of the face or throat, or neurological symptoms should prompt immediate medical evaluation.

Influvac should not be given to individuals with a known severe allergy to any component of the vaccine, including egg protein if present, or to those who have experienced a previous anaphylactic reaction to an influenza vaccine. Persons with a current severe febrile illness should defer vaccination until they recover.